Biologically active amides
Abstract
Abstract Novel peptide compounds of the formula X.sup.1 --X.sup.2 --X.sup.3 --X.sup.4 --X.sup.5 --X.sup.6 --X.sup.7 --X 8 --Pro--W are provided together with their acid addition salts and their complexes with pharmaceutically acceptable metals. The compounds are LH-RH analogues and together with their salts and complexes exhibit LH-RH antagonist activity. In the formula X 1 is selected from pyroglutamyl, a group V 1 -Pro- where V 1 is acyl, alkyloxycarbonyl or aralkyloxycarbonyl, and a group V 2 --CO-- where V 2 is cycloalkyl; X 2 is selected from histidyl and a direct bond; X 3 is selected from phenylalanyl optionally substituted in the benzene ring and tryptophyl; X 4 is selected from glycyl, seryl, alanyl (D- or L), D-leucyl and D-valyl; X 5 is phenylalanyl optionally substituted in the benzene ring; X 6 is selected from glycyl, alanyl (D- or L-), D-leucyl and D-valyl; X 7 is selected from phenylalanyl optionally substituted in the benzene ring and leucyl; X 8 is a direct bond when X 2 is histidyl and is otherwise arginyl or homoarginyl; and W is selected from glycine amide and a group --NR 1 R 2 where R 1 , R 2 and the nitrogen atom together comprise a group selected from amino, N-alkylamino, N,N-dialkylamino, pyrrolidino, morpholino and 1-methyl-5-aminomethyltetrazolyl, the `alkyl` having from 1 to 4 carbon atoms and being optionally substituted by an hydroxyl group, provided that, when X 1 , X 3 , X 4 , X 5 , X 7 and X 8 are respectively pyroglutamyl, tryptophyl, seryl, tyrosyl, leucyl and arginyl, W is other than glycine amide or N-ethylamino when X 6 is glycyl and is other than glycine amide when X 6 is D-alanyl. All references are to the L-amino acids and their radicals except in the case of glycine and unless otherwise stated. Also provided are methods for the preparation of the peptides, salts and complexes, pharmaceutical formulations containing them and methods for the preparation of such formulations, and methods for the use of the peptides, salts and complexes in human and in veterinary medicine.
Inventors
- 👤 Christopher Raymond Beddell
- 👤 Lawrence Alfred Lowe
- 👤 Samuel Wilkinson
Bibliographic Details
Claims Analysis
Total Claims: 12References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-02-20 | 1981-08-22 | 1982-02-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-02-20 | 1985-08-22 | 1986-02-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-02-20 | 1989-08-22 | 1990-02-21 | $7700.00 | Window Closed / Lapsed |